Business Daily Media

Business Marketing

.

Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk

  • Written by ACN Newswire
image
SYDNEY, Mar 25, 2019 - (ACN Newswire) - Clinical Network Services (CNS) USA, an integrated services group focused on clinical product development and subsidiary of Asia-Pacific specialist CRO Novotech, today announced the appointment of Dr Robert Malone as Principal Consultant in its Washington D.C. office. CNS is headquartered in Australia with offices in New Zealand, the UK and the USA.

Dr Malone brings more than 20 years of management and leadership experience in academia, pharmaceuticals and biotechnology, with deep expertise in regulatory and medical strategy for global clinical product development. Dr Malone is an internationally recognised physician and scientist for his work in clinical trials in the areas of vaccines, gene therapy, biodefense and immunology, and specifically as one of the original inventors of DNA vaccination and multiple non-viral gene therapy technologies (RNA and DNA).

Commenting on the new role, Robert said: "I am delighted to join the CNS BioDesk USA consulting team; this is an exciting opportunity to work within a highly professional and experienced group that is dedicated to adding value to clients' early phase programs and their US regulatory strategies."

Russell Neal, CNS Managing Director said: "Dr Malone brings a wealth of industry and consulting experience to our US BioDesk team, and his appointment reflects CNS' ongoing commitment to the continuous growth and evolution of BioDesk to service CNS' international clients as they navigate US and global regulatory strategies."

CNS' BioDesk division is an intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval. It is a uniquely internationally experienced team with particular expertise in the areas of vaccines, oncology, infectious disease as well as cell and gene therapies.

CNS and Novotech, the largest Asia-Pacific-based CRO, merged in late 2018 as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials.

About Clinical Network Services Clinical Network Services (CNS) is an integrated services group focused on product development based in Australia with offices in New Zealand, the UK and the USA, which creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials and the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with a committed, highly experienced Australian/New Zealand clinical services and biometrics team. More about CNS and its intelligent development services at www.clinical.net.au[1]

About BioDeskCNS' BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. More about BioDesk services can be found at www.cnsbiodesk.com[2]

About Novotech - https://novotech-cro.com/welcome[3]Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. For more, see www.novotech-cro.com[4].

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0[5]

Media Contact:[email protected]Susan Fitzpatrick-Napier, AU: +61 2 8218 2144 USA: +1 415 951 3228, Asia: +65 3159 3427[6]

Topic: Press release summarySectors: HealthCare[7] http://www.acnnewswire.com From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

References

  1. ^ www.clinical.net.au (www.clinical.net.au)
  2. ^ www.cnsbiodesk.com (www.cnsbiodesk.com)
  3. ^ https://novotech-cro.com/welcome (novotech-cro.com)
  4. ^ www.novotech-cro.com (www.novotech-cro.com)
  5. ^ www.novotech-cro.com/contact-us-0 (www.novotech-cro.com)
  6. ^ [email protected] (www.acnnewswire.com)
  7. ^ HealthCare (www.acnnewswire.com)

Read more http://www.acnnewswire.com/press-release/english/50583/

Popular

5 Key Considerations When Outsourcing Technical Support

Many large companies use outsourced technical support as a cost-effective way to handle incoming support requests from their customers. Often, these organizations pick up and drop off this service quickly because they feel tha...

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Antengene recently unveiled a new office space situated in Melbourne’s most sought-after CBD, taking another important step in the company’s continued global expansion. The new office offers an appealing environment that will ...

Home Buyers Move North as a Result of Interest Rates

SOUTHERN STATE EXODUS CONTINUES FOLLOWING INTEREST RATE RISES As many as 1 in 4 buyers are still inspecting property outside the state they live in, a trend that’s showing no signs of slowing as interest rates rise and housing...